Insights
Insights From Our Experts
Articles
Navigating the Complexities of Patient Care with Digital and Human Touchpoints
Three Key Objectives Guide Program Development: Access, Affordability and Adherence Patients taking branded therapies to manage long-term health conditions are faced with a dizzying array of challenges, all of which can hinder access to medication, create…
Pharmaceutical Distribution – Right-Sizing the Channel Strategy for Maximum Impact
In recent years, there has been increasing appetite among manufacturers — and growing capabilities among specialized channel-distribution service providers — to shorten the value chain. When drug manufacturers reflexively commit to a distribution model that is…
FDA Moves Cybersecurity Into the Product Life Cycle
Due to rising cyber-attacks and the potential to cause harm to patients, medical facilities and hospitals, the U.S. Food and Drug Administration (FDA) has recently increased scrutiny of cyber controls in FDA premarket submissions of medical…
Impact of Patient Reported Outcome Measures on HTA Decisions for Rare Diseases
As rare diseases become an increasing area of global focus, pharmaceutical manufacturers are taking a closer look at how patient-reported outcomes (PROs) may be used to improve uptake in HTA evaluations. Although “rare” suggests not many…
EVERSANA Featured in NIH Study Detailing the Cost of Treating Rare Disease
“The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems” EVERSANA™ was the only data and analytic organization invited by a consortium of provider organizations and the NIH to…
Reigniting Revenue for Established Brands
Established brands do not require significant proactive investment or attention from commercial teams and generate revenue for biopharma companies to reinvest and improve healthcare value for patients, providers and payers. Established brands have seen a decrease…
Reignite Established Brands — Actual Use Case
EVERSANA™ REIGNITE Commercialization serves as a catalyst for biopharma companies to address the management of their established brand portfolios. In a recent study, EVERSANA reviewed a comprehensive number of established brands and implemented the EVERSANA REIGNITE…
Reframing the Challenges of Access and ROI
Pharma companies today are being judged not just on their profitability for shareholders, but also on the extent to which their products are accessible to patients. Today’s Environmental, Social and Governance (ESG) investors want to see…
What You Need to Know as the European Union Embarks on Joint Health Technology Assessment (HTA)
Facing the “Fourth Hurdle” Member states of the European Union benefit from a centralised marketing authorisation process for medicinal products. Also, since its implementation in 1993, the European Medicines Agency (EMA) has assured pharmaceutical companies the…
New Legislation Supports Payment for Digital Therapeutics
Earlier this month, the Access to Digital Prescription Therapeutics Act of 2022 was introduced by Rep. Mike Thompson (D-CA) to the U.S. House of Representatives as H.R. 7051 and by Sen. Shelley Moore Capito (R-WV) to…